Form 8-K - Current report:
SEC Accession No. 0001104659-25-055521
Filing Date
2025-06-02
Accepted
2025-06-02 17:00:35
Documents
12
Period of Report
2025-06-02
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2516951d1_8k.htm   iXBRL 8-K 21455
  Complete submission text file 0001104659-25-055521.txt   186157

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250602.xsd EX-101.SCH 3047
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250602_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250602_pre.xml EX-101.PRE 22380
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2516951d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 251015917
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)